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As a population, hematopoietic stem cells 
(HSCs) have the remarkable ability to drive 
hematopoiesis for the lifetime of the organism 
while maintaining and even expanding their 
numbers with age (1). The capacity of stem 
cells to both self-renew and yet maintain 
  multilineage potential appears to be dependent 
on the localization of HSCs within specifi  c 
microenvironments within the bone marrow 
because other organs associated with extra-
medullary hematopoiesis, such as the spleen, 
cannot maintain the self-renewal potential of 
HSCs (2). Although the molecular and cellular 
details of these HSC niches are only just 
  beginning to be revealed (3–6), in normal 
  settings it is likely that these specialized micro-
environments are as rare as the HSCs they sup-
port. Another hallmark property of HSCs is 
their intrinsic ability to home to these very 
specifi  c niches within the bone marrow after 
intravenous transplantation. Upon adoptive trans -
fer into myeloablated recipients, single HSCs 
can give rise to all of the blood lineages for the 
lifetime of the recipient (7, 8). Transplanta  -
tion into unconditioned recipients, how  ever, 
has led to mixed results. Transplantation of ex-
traordinarily high doses of unfractionated con-
genic bone marrow or populations enriched 
for HSCs has led to hematopoietic chimerism 
(9, 10), although it is unclear whether this do-
nor contribution is indicative of HSC engraft-
ment and multilineage reconstitution, or solely 
the survival of lymphoid cells, which can persist 
for long periods of time in the absence of fur-
ther input from the bone marrow (11–13). In 
contrast, conventional intravenous transplan-
tation of more moderate amounts of conge-
nically marked syngeneic or allogeneic bone 
mar    row or purifi  ed HSCs rarely, if ever, leads 
to sustained multilineage engraftment without 
irradiation of the recipient (14, 15). Thus, the 
bulk of evidence has suggested that HSC niches 
are fi  lled under normal conditions.
Recent evidence, however, has suggested 
that a small fraction of HSC niches may be 
available in normal animals. First,  100 HSCs 
<doi> 10.1084/jem.200517 14 </doi><aid>20051714</aid>Purifi  ed hematopoietic stem cell engraftment 
of rare niches corrects severe lymphoid 
defi  ciencies without host conditioning
Deepta Bhattacharya, Derrick J. Rossi, David Bryder, 
and Irving L. Weissman
Department of Pathology, Institute of Cancer and Stem Cell Biology and Medicine, Stanford University School of Medicine, 
Stanford, CA 94305
In the absence of irradiation or other cytoreductive conditioning, endogenous hematopoi-
etic stem cells (HSCs) are thought to fi  ll the unique niches within the bone marrow that 
allow maintenance of full hematopoietic potential and thus prevent productive engraft-
ment of transplanted donor HSCs. By transplantation of purifi  ed exogenous HSCs into 
unconditioned congenic histocompatible strains of mice, we show that  0.1–1.0% of these 
HSC niches are available for engraftment at any given point and fi  nd no evidence that 
endogenous HSCs can be displaced from the niches they occupy. We demonstrate that 
productive engraftment of HSCs within these empty niches is inhibited by host CD4+ T cells 
that recognize very subtle minor histocompatibility differences. Strikingly, transplantation 
of purifi  ed HSCs into a panel of severe combined immunodefi  cient (SCID) mice leads to a 
rapid and complete rescue of lymphoid defi  ciencies through engraftment of these very rare 
niches and expansion of donor lymphoid progenitors. We further demonstrate that tran-
sient antibody-mediated depletion of CD4+ T cells allows short-term HSC engraftment and 
regeneration of B cells in a mouse model of B(-) non-SCID. These experiments provide a 
general mechanism by which transplanted HSCs can correct hematopoietic defi  ciencies 
without any host conditioning or with only highly specifi  c and transient lymphoablation.
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can be found at any given time in the peripheral blood of a 
normal mouse, and these cells are capable of reconstituting 
irradiated mice and functionally engraft unnirradiated part-
ners in a parabiotic model (16). Blood HSCs have a resi-
dence time in blood of  1 min, and so to maintain a 
steady-state of 100 HSCs, upwards of 30,000 HSCs per day 
fl  ux through the blood of a mouse (16). Although the etio-
logic reasons are unclear, the presence of these cells in the 
blood suggests that HSCs may exist in a dynamic equilib-
rium with their environment and that a certain number of 
bone marrow niches may be available for engraftment at 
any given point. Second, several recent studies using un-
fractionated bone marrow transplants have shown that the 
small congenic diff  erences used to distinguish donor-de-
rived hematopoietic cells from the recipient’s endogenous 
cells constitute a signifi  cant immunologic barrier (17, 18). 
Figure 1.  Donor HSCs can engraft unconditioned tolerant wild-
type hosts. (A) Persistent multilineage contribution occurs only in 
tolerant recipients. 4,000 ckit+ Thy1.1low lineage− Sca-1+ Flk2− CD34− 
HSCs from male CD45.1 mice were transplanted into unirradiated male 
CD45.1 × CD45.2 (F1), CD45.2, or irradiated male CD45.1 × CD45.2 
recipients. Granulocytes were pregated as side scatterhigh B220− 
TCRβ− cells, B cells were pregated as Mac-1− TCRβ− cells, and T cells 
were pregated as B220− Mac-1− cells. Representative plots of 
  peripheral blood at 16 wk after transplantation are presented. 
(B) Consistent granulocyte contribution in tolerant hosts. Granulocyte 
chimerism is shown at 4-wk intervals after transplantation into 
CD45.1 × CD45.2 and CD45.2 hosts. ◇, F1 hosts; ●, CD45.2 recipients. 
Data points below the dotted line represent animals with no 
detectable chimerism.JEM VOL. 203, January 23, 2006  75
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These studies suggest that the absence of donor-derived 
cells in unconditioned hosts receiving congenic hemato-
poietic transplants may be a refl  ection of immunologic re-
jection rather than a lack of open HSC niches.
To assess the role of immunosurveillance and to quantify 
the number of available HSC niches in normal and immuno-
defi  cient animals, we performed a series of HSC transplants 
into histocompatible hosts and recipients with a minor histo-
compatibility mismatch at a single locus. We show that trans-
planted HSCs can productively engraft  0.1–1.0% of HSC 
niches in H2-matched, minor histocompatibility– mismatched 
unconditioned hosts, but only if host CD4+ T cells are absent 
or genetically unreactive to the graft. Large excesses of trans-
planted HSCs do not signifi  cantly increase this engraftment, 
suggesting that endogenous HSCs residing in appropriate 
niches cannot be easily displaced. Despite the small numbers 
of available HSC niches, we show that transplantation of pu-
rifi  ed HSCs is suffi   cient to permanently   rescue animals with 
severe immunodefi   ciencies by regenerating donor-derived 
lymphocytes to normal levels through expansion of progeni-
tor cells within the unfi  lled lymphoid compartments. The 
mechanism by which purifi  ed HSC transplantation corrects 
lymphoid disorders is likely to be broadly applicable to the 
treatment of hematopoietic defi  ciencies.
RESULTS
Immune surveillance prevents engraftment of subtly 
mismatched HSCs
HSCs in 4,000 ckit+ Thy1.1low lineage− Sca-1+ Flk2− 
CD34− cells from CD45.1 mice were transplanted intrave-
nously into fi  ve unnirradiated CD45.1 × CD45.2 (F1) and 
fi  ve unirradiated congenic CD45.2 mice. Every 4 wk after 
transplantation, peripheral blood was analyzed for granulo-
cyte, B cell, and T cell chimerism. Donor granulocyte chi-
merism, which accurately refl  ects HSC chimerism (16), was 
observed only in the genetically unreactive F1 recipients at 
all time points analyzed with a median chimerism at 16 wk of 
 0.1% (Fig. 1). [ID]FIG1[/ID] These data demonstrate that the subtle anti-
genic diff  erences that exist between these CD45 congenic 
strains of mice are suffi     cient to prevent productive HSC 
cross-engraftment.
Rapid HSC-mediated correction of lymphoid defi  ciencies in 
SCID mice
To gauge the potential clinical importance of these rare avail-
able niches, we repetitively transplanted HSCs from GFP-
transgenic mice into RAG2 and IL-2 receptor common γ 
chain–defi  cient (RAG2−/−γc−/−) mice, which lack B, T, 
and NK cells (19). Enormous numbers of donor-derived B 
and T cells were found in the blood at all time points, leading 
to an overall donor chimerism of  50% until at least 30 wk 
after the fi  nal transplantation (Fig. 2, A and B). [ID]FIG2[/ID] Donor NK 
cells were also detected in all transplanted animals (not de-
picted). Moreover, all RAG2−/−γc−/− mice displayed persis-
tent donor-derived myeloid chimerism (ranging from 0.5 to 
2.0% donor-derived granulocytes).
To confi  rm that the donor granulocyte frequencies ac-
curately refl  ected bone marrow HSC chimerism, we killed 
animals at 30 wk after transplant and analyzed bone marrow. 
Donor cells comprised  0.8% of the total long-term (LT)-
HSC pool (Fig. 3 A). [ID]FIG3[/ID] This chimerism was essen-tially the 
same in the short-term reconstituting stem cells (ckit+ lin-
eage− Sca-1+ CD34+ Flk2−) and the multipotent progeni-
tors (ckit+ lineage− Sca-1+ CD34+ Flk2+; not depicted). We 
were unable to detect any cells with these surface pheno-
types in the spleen, a major organ associated with extramed-
ullary hematopoiesis (not depicted). These data confi  rmed 
that in these animals, peripheral donor granulocyte frequen-
cies much more accurately refl  ect HSC chimerism than the 
overall donor contribution in the blood. The data also dem-
onstrate that small numbers of bone marrow–engrafted HSCs 
can correct severe lymphoid defi  ciencies without prior cyto-
reductive conditioning. The HSC chimerism in the RAG2−/−
γc−/− mice was comparable to the chimerism seen in the ge-
netically unreactive F1 wild-type mice (Fig. 1), demonstrat-
ing that there are not obviously greater numbers of available 
HSC niches in these animals.
To confi   rm that functional HSCs had engrafted, we 
  isolated bone marrow at 31 wk after transplant from unir-
radiated RAG2−/−γc−/− mice that had received GFP+ HSC 
transplants and performed secondary transplants using either 
Figure 2.  Small numbers of engrafted wild-type HSCs can rescue 
lymphocyte defi  ciencies in unnirradiated RAG2−/−𝗄c−/− mice. 
(A) Robust donor chimerism in unconditioned RAG2−/−γc−/− recipients. 
Unirradiated RAG2−/−γc−/− mice were repetitively transplanted six times 
with 1,750–4,000 HSCs from eGFP-transgenic mice, and peripheral blood 
was analyzed for donor myeloid and lymphoid contribution at 4 wk after 
the fi  nal transplant. Granulocytes were pregated as side scatterhigh B220− 
TCRβ− cells, B cells were pregated as Mac-1− TCRβ− cells, and T cells were 
pregated as B220− Mac-1− cells. (B) Persistent multilineage contribution 
in unnirradiated RAG2−/−γc−/− recipients. Peripheral blood was analyzed 
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unfractionated or c-kit–enriched marrow, which increases 
the frequency of HSCs by  10-fold, into lethally irradiated 
wild-type mice, such that  6–20 GFP+ HSCs along with 
1,000 RAG2−/−γc−/− HSCs were transferred into each 
  secondary recipient. Donor-derived GFP+ cells were ob-
served in all secondary recipients until at least 25 wk after 
transplantation, and 6 out of 13 secondary recipients main-
tained detectable levels of granulocyte chimerism (Fig. 
3  B). These data confi  rmed that rare GFP+ HSCs within 
the bone marrow of the primary RAG2−/−γc−/− recipients 
had productively engrafted. In contrast, transplantation of 
large numbers of splenocytes into secondary recipients did 
not lead to sustained multilineage stem cell reconstitution 
(not depicted).
Opportunistic expansion of donor lymphoid progenitors
To determine the developmental stage at which donor B cells 
overtake host B cells in RAG2−/−γc−/− recipients, we ana-
lyzed donor frequencies in myeloid and lymphoid progenitor 
cells in the bone marrow. Common myeloid progenitors 
(CMPs; reference 20) and common lymphoid progenitors 
(CLPs; references 21–23) showed donor chimerism that was 
comparable to HSC chimerism (Fig. 4), indicating that do-
nor-derived cells do not have a competitive proliferative ad-
vantage at these early developmental steps. [ID]FIG4[/ID] Donor chimerism 
at the granulocyte macrophage progenitor (GMP) and mega-
karyocyte erythrocyte progenitor (MEP) developmental steps 
were also similar to HSC chimerism (not depicted). Consis-
tent with these results, the frequencies of endogenous HSCs, 
CLPs, CMPs, GMPs, and MEPs within the bone marrow are 
similar between untransplanted wild-type and RAG2−/−
γc−/− mice (Fig. 5).[ID]FIG5[/ID] Analysis of the pro–B-A and pro–B-B 
cell fractions (24, 25), however, showed donor chimerism 
that was dramatically higher than the preceding CLP (Fig. 4). 
At the pro–B-B cell stage and all subsequent B cell stages, 
cells were exclusively donor-derived. Although IL-7 recep-
tor, which uses γc for proper signaling, is expressed at the 
CLP stage, these results suggest that IL-7 signaling is not a 
Figure 3.  Low-level HSC engraftment in primary unconditioned 
RAG2−/−𝗄c−/− recipients. (A) Donor HSCs can be detected in primary 
unirradiated RAG2−/−γc−/− recipients. At 31 wk after the fi  nal trans-
plantation, donor HSC contribution in the bone marrow in uncondi-
tioned primary RAG2−/−γc−/− recipients was quantifi  ed using the 
markers shown. (B) Engrafted HSCs in the bone marrow of uncondi-
tioned primary RAG2−/−γc−/− recipients can be serially transplanted. 
Unfractionated (5 × 107) or c-kit–enriched (106) bone marrow cells 
from primary RAG2−/−γc−/− recipients were secondarily transplanted 
into lethally irradiated (950 cGy) wild-type mice. GFP+ chimerism 
was assessed at 25 wk after secondary transplantation. Each second-
ary recipient received a transplant from a distinct nonredundant 
  primary donor. Data points below the dotted line represent undetect-
able chimerism.JEM VOL. 203, January 23, 2006  77
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requisite pathway for CLP development or expansion, con-
sistent with previous observations (26).
Normal immune responses in HSC-reconstituted SCID mice
To verify that the immune system of the HSC-reconstituted 
RAG2−/−γc−/− mice had been restored and was capable of 
mounting appropriate immune responses, we immunized re-
constituted recipients with alum-precipitated 4-hydroxy-3-
nitrophenylacetyl (NP) conjugated to chicken γ globulin, 
which elicits a Th2-dependent humoral response (27, 28). 
Serum levels of NP-specifi  c antibody were similar at 1 wk after 
immunization between HSC-transplanted RAG2−/−γc−/− 
and wild-type mice, demonstrating the immunocompetence 
of the transplanted RAG2−/−γc−/− recipients (Fig. 6). [ID]FIG6[/ID]
Host CD4+ T cells are essential for rejection of subtly 
mismatched HSCs
To investigate whether the absence of γc was critical for 
HSC engraftment in unconditioned hosts, perhaps by im-
parting a competitive disadvantage on HSCs in RAG2−/−
γc−/− animals, we transplanted GFP+ HSCs into RAG2−/− 
mice, which have normal γc expression, as well as into 
RAG2−/−γc−/− mice. As shown in Fig. 7, similar levels of 
donor granulocyte contribution were seen in RAG2−/− and 
RAG2−/−γc−/− mice, likely excluding a direct role for γc in 
maintaining host HSCs within their niches. [ID]FIG7[/ID] However, γc ex-
pression has been observed in normal HSCs (29), suggesting 
that there may be a slight competitive advantage for HSCs 
with proper γc expression. The data also suggest that NK 
cells, which are present in normal numbers in RAG2−/− 
mice but absent in RAG2−/−γc−/− mice, are not mediating 
HSC rejection in this H2-identical system. Elimination of 
host NK cells is required for engraftment of HSCs that carry 
one or more unshared H2 haplotype (30). Interestingly, do-
nor-derived lymphocyte frequencies were signifi  cantly re-
duced in RAG2−/− recipients at early time points (Fig. 7 B), 
perhaps as a result of the occupation of the lymphoid stage–
specifi  c stromal environments by RAG2−/− lymphoid pro-
genitors (31). The number of donor-derived B cells in 
RAG2−/− recipients was reduced more than 10-fold relative 
to RAG2−/−γc−/− recipients at 4 wk after transplant, and 
peripheral T cells were not seen at all until 8 wk after trans-
plant (not depicted). However, by 16 wk after transplanta-
tion, B and T cell numbers in RAG2−/− recipients reached 
the levels seen in their RAG2−/−γc−/− counterparts (Figs. 
7 B and 8 A). [ID]FIG8[/ID]
Because RAG2−/− mice lack both mature B and T cells, 
we sought to determine which of these cell types was primar-
ily responsible for mediating the rejection of transplanted do-
nor HSC grafts. Therefore, we transplanted   purifi  ed HSCs 
from GFP donor mice into unnirradiated TCRα−/−β−/− 
and Cμ−/− mice. In these experiments, known antigenic 
diff  erences between donor HSCs and recipient mice exist at 
the GFP, CD45, and Thy1 loci. Multilineage engraftment 
was observed in T cell–defi  cient mice, but not in B cell–
  defi  cient mice (Fig. 8 A). These experiments show that host 
αβ T cells are required for the rejection of HSC grafts with 
these minor histocompatibility mismatches. To determine 
which class of T cells is essential for this immunosurveillance, 
we transplanted HSCs into unconditioned I-A−/− mice, 
which lack MHC II–restricted CD4+ T cells (32), and β2-
microglobulin−/− (β2m−/−) mice, which are defi  cient in 
MHC I–restricted CD8+ T cells (33). The HSC-transplanted 
Figure 5.  Stem and progenitor cell frequencies are normal in 
RAG2−/−𝗄c−/− mice. LT-HSCs, ST-HSCs, and multipotent progenitors 
were stained from untransplanted mice as in Fig. 2. CLPs and CMPs were 
stained as in Fig. 4. MEPs and GMPs were stained according to established 
protocols (reference 20). Each endogenous population is presented as a 
percentage of total bone marrow. ○, wild-type animals; ◇, RAG2−/−
γc−/− mice.
Figure 6.  Reconstituted RAG2−/−𝗄c−/− mice can respond normally 
to antigenic challenge. RAG2−/−γc−/− mice were immunized with 100 
μg alum-precipitated NP–chicken γ globulin 16 wk after HSC transplant. 
Serum was obtained 1 wk after immunization and tested for NP-specifi  c 
antibodies. Mice with undetectable serum levels of NP-specifi  c IgG are 
shown below the dotted line.
Figure 4.  Signifi  cant donor cell expansion is not observed until 
the pro–B cell stage. At 31 wk after the fi  nal transplantation, donor 
contribution to myeloid and lymphoid progenitor cells was analyzed. 
CMPs were defi  ned as lin− ckit+ Sca-1− CD16/32low CD34low cells. CLPs 
were gated as lin− Thy1.1low IL7Rα+ Flk2+ ckitlow Sca1low cells. Pro–B-A 
cells were defi  ned as B220+ CD43+ IgM− CD19− NK1.1−, and pro–B-B 
cells were gated as B220+ CD43+ IgM− CD19+ Ly51− NK1.1− cells. Mean 
values ± SEM are shown from the analysis of three mice for each subset.78  ENGRAFTMENT IN RARE EMPTY HEMATOPOIETIC STEM CELL NICHES | Bhattacharya et al.
I-A−/− mice showed sustained chimerism until at least 16 
wk, whereas the β2m−/− recipient mice did not show chime-
rism at any time point (Fig. 8 B), thereby demonstrating that 
CD4+ T cells are essential for the rejection of minor histo-
compatibility–mismatched HSC grafts in our system. LT-
HSCs express MHC II (Fig. 8 C) and the costimulatory 
molecule CD86 (29), suggesting that host CD4+ T cells may 
directly recognize HSCs with slight antigenic mismatches. 
Although it appears that CD8+ T cells are not required for 
this rejection, we cannot exclude the possibility that residual 
hyperreactive MHC I–restricted T cells might also contribute 
to HSC graft rejection in the β2m−/− mice (34–36). Consis-
tent with the role for CD8 T cells in mediating bone marrow 
graft rejection, Xu et al. (17) have shown that host CD8 de-
fi  ciency enhances engraftment.
Interestingly, the granulocyte chimerism in the RAG2−/− 
recipients was indistinguishable from that seen in previous 
experiments in which 3,000 HSCs rather than 1,000 were 
transplanted (Fig. 7). In contrast, although transplantation of 
20 HSCs led to detectable B and T cell production in these 
immunodefi   cient mice, granulocyte chimerism was barely 
detectable (not depicted). Thus, our experiments suggest that 
HSC engraftment and chimerism asymptotically approaches a 
maximum of  0.5% in a cell dose–dependent manner. The 
data show that in contrast to previous speculations, endoge-
nous HSCs cannot be displaced from the niches they occupy 
by increasing transplanted HSC numbers above a threshold 
level. In repetitively transplanted mice, however, we have 
observed small increases in granulocyte chimerism relative to 
mice that were HSC-transplanted only once with doses above 
this threshold (Fig. 2 B vs. Fig. 7 B). This provides evidence 
that transplantation of an excess of HSCs does not preclude 
additional niches from being vacated in the future.
To determine if transient CD4+ T cell removal would 
  allow access of transplanted HSCs to appropriate niches, we 
treated Cμ−/− mice with a depleting CD4 antibody that led 
to  95% depletion of peripheral blood CD4+ T cells (Fig. 9 
A).[ID]FIG9[/ID] CD4-depleted mice were then transplanted with 800 
HSCs and analyzed at various time points for donor chime-
rism. All mice that received anti-CD4 treatment showed 
Figure 7.  𝗄c expression is not directly important for HSC mainte-
nance. (A) Purifi  ed wild-type HSCs can engraft unirradiated RAG2−/− 
mice. Unconditioned RAG2−/− and RAG2−/−γc−/− mice were transplanted 
with 3,000 HSCs from GFP-transgenic mice. Representative plots from 
peripheral blood obtained 4 wk after transplantation are shown. Granulo-
cytes were pregated as side scatterhigh B220− CD3− cells, B cells were 
pregated as Mac-1− CD3− cells, and T cells were pregated as B220− 
Mac-1− cells. (B) Persistent granulocyte chimerism but delayed lymphoid 
  reconstitution in RAG2−/− mice. ◇, RAG2−/−γc−/− animals; 
●, RAG2−/− animals.JEM VOL. 203, January 23, 2006  79
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  donor granulocyte chimerism, whereas none of the untreated 
mice displayed any detectable donor cells at 8 wk after trans-
plantation (Fig. 9 B). Signifi  cant numbers of donor B cells 
were observed in the treated mice at 6–8 wk after transplan-
tation, again demonstrating the ability of small numbers of 
productively engrafted HSCs to restore lymphocyte numbers 
in immunodefi  cient mice. Because host CD4+ T cells levels 
were noted to recover subsequent to immunodepletion (not 
depicted), these experiments demonstrate that transient de-
pletion of these cells before transplantation is suffi   cient to al-
low for productive short-term stem cell engraftment without 
the need for the standard toxic cytoreductive drugs com-
monly used for B(-) non-SCID patients before bone marrow 
transplant (37). However, by 12 wk after HSC transplanta-
tion, donor B cell, T cell, and myeloid chimerism was lost in 
all recipient mice (not depicted). These data suggest that ei-
ther the α-CD4–mediated depletion of mature T cells was 
incomplete, or that suffi   cient numbers of donor-derived den-
dritic cells were not generated to mediate lasting tolerance 
through negative selection in the thymus (38).
Short-term reconstitution in unconditioned aged recipients
Aged individuals show marked reductions in thymus size 
and T cell function (39). To determine if the reduced lym-
phoid function in aged mice would allow acceptance of 
transplants without conditioning, we repetitively trans-
planted HSCs from GFP-transgenic mice into old (22 mo) 
and young (2 mo) recipients. As seen in Fig. 10, short-term 
low-level myeloid chimerism was observed in all old re-
cipients in contrast to the young recipients that showed 
no engraftment. [ID]FIG10[/ID] However, donor-derived cells declined 
to undetectable levels in all but one of the old recipients 
with time, suggesting that rejection of the transplants did 
occur, but with signifi  cantly reduced kinetics relative to 
the younger animals (not depicted). The level of granulo-
cyte chimerism in this experiment was similar to the low 
levels seen in transplants of younger, genetically unreactive 
or immunodefi  cient mice, suggesting that aged HSCs can-
not be displaced from their endogenous niches. This is in 
contrast to previous studies performed with unfractionated 
bone marrow transplants (40) and suggests that reduced 
Figure 8.  Host T cells act as barriers to productive HSC engraft-
ment. (A) α/β T cells are required for HSC graft rejection. 1,000 puri-
fi  ed HSCs from eGFP-transgenic mice were transplanted into 
TCRα−/−β−/−, Cμ−/−, RAG2−/−, and wild-type animals. Peripheral 
blood was analyzed for donor cell contribution at 16 wk after trans-
plantation. Granulocytes were pregated as side scatterhigh B220− 
TCRβ− cells, B cells were pregated as Mac-1− TCRβ− cells, and T cells 
were pregated as B220− Mac-1− cells. A representative plot for each 
group is shown. (B) Host CD4+ T cells are essential for HSC graft rejec-
tion. 800 purifi  ed HSCs from GFP-transgenic mice were transplanted 
into 2 I-A−/− and 3 β2m−/− mice. Peripheral blood was analyzed 16 wk 
after transplantation for donor chimerism. Representative plots are 
shown. (C) LT-HSCs express MHC II. MHC II expression was analyzed on 
LT-HSCs from wild-type animals.80  ENGRAFTMENT IN RARE EMPTY HEMATOPOIETIC STEM CELL NICHES | Bhattacharya et al.
  immune capacity is responsible for short-term engraftment 
of donor HSCs.
DISCUSSION
The remarkable ability of HSCs to sustain multilineage he-
matopoiesis for the lifetime of an individual constitutes the 
foundation for their routine use in a range of clinical appli-
cations, including the treatment of primary immunodefi  -
ciencies (41, 42), malignancies (43–45), as conditioners for 
transplantation tolerance of tissue or organ grafts from the 
donors (46), and as a method to reverse some types of auto-
immunity (47). The success of such therapies relies on the 
ability of HSCs to home to unique niches leading to sus-
tained multilineage hematopoiesis. The studies presented 
here have quantifi  ed the number of these HSC niches that 
are available for engraftment at any given point in uncondi-
tioned animals as  0.1–1.0% of all HSC niches. Assuming a 
total adult murine bone marrow cellularity of 5 × 108 cells 
(48) and an endogenous HSC frequency of 0.01% (Fig. 4), 
the number of open HSC niches can be estimated to be 50–
500. This is strikingly similar to the number of HSCs esti-
mated to be in circulation at any given point (16). The data 
suggest that HSCs that circulate normally have exited and left 
vacant their previous HSC niche. Thus, a constant exchange 
may be occurring between endogenous HSCs under normal 
circumstances, perhaps to maintain hematopoietic balance 
between and within each bone marrow compartment. In sup-
port of this, we have found little diff  erence in the granulocyte 
Figure 9.  Transient CD4 depletion allows productive engraft-
ment of HSCs with minor histocompatibility mismatches. (A) Treat-
ment of Cμ−/− mice with a depleting antibody leads to effi  cient CD4+ 
T cell removal. Mice were treated consecutively for 3 d with anti-CD4 
antibody, and peripheral blood was analyzed for TCRβ+ CD8− cells to 
assess depletion 1 d after the fi  nal treatment. The plots are gated on 
Ter119− TCRβ+ cells. (B) HSC engraftment occurs in anti-CD4–treated 
animals. Three Cμ−/− mice that were treated with anti-CD4 antibody 
and two Cμ−/− mice that were left untreated were transplanted with 
800 GFP+ HSCs. Peripheral blood was analyzed at 8 wk after transplan-
tation for granulocyte, B cell, and T cell chimerism. Granulocytes 
were pregated as side scatterhigh B220− CD3− cells, B cells were pre-
gated as Mac-1− CD3− cells, and T cells were pregated as B220− Mac-1− 
cells. Representative plots are shown. (C) Signifi  cant short-term multi-
lineage engraftment in all anti-CD4–treated recipients. Donor con-
tribution to granulocytes, T cells, and B cells at 8 wk after HSC 
transplant is shown. B cells are quantifi  ed as number of cells contained 
within 100 μl of peripheral blood. ◇, anti-CD4–treated animals; 
●, untreated animals. Data points that were undetectable are shown 
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chimerism rates between experiments when a single trans-
plant of HSCs is provided in doses ranging from 800 to 4,000 
cells. Although previous reports have suggested that the cell 
doses of transplanted bone marrow correlate with total chi-
merism linearly, such data at most show replacement of bone 
marrow and mature cells in bulk and do not refl  ect replace-
ment of HSCs, which represent only 0.01% of unfractionated 
marrow (9). When HSCs are repetitively transplanted, how-
ever, we have observed increases in granulocyte chimerism 
(Fig. 2 B vs. Fig. 7 B). Thus, occupation of available HSC 
niches after transplantation of an excess of exogenous HSCs, 
which remain in circulation for  1–5 min after transplanta-
tion (16), does not preclude additional niches from   becoming 
available subsequently. Conceivably, continuous transfusion 
of low numbers of HSCs would be superior to singly admin-
istered boluses, as the rate of niche emptying and fi  lling is 
high. Because there does not appear to be an obvious increase 
in granulocyte chimerism with time or cell dose above a 
threshold level, the data also suggest that transplanted HSCs 
must fi  nd their way rapidly to an appropriate niche and can-
not recirculate indefi  nitely in search of empty niches without 
the loss of hematopoietic potential.
The ability of transplanted HSCs to self-renew for the 
lifetime of the organism ensures a constant production of 
normal lymphoid cells through each developmental stage. In 
the genetic mutants used in our work, host lymphocyte de-
velopment is blocked or perturbed at defi  ned developmental 
stages. At each developmental stage or thereafter, wild-type 
donor cells have a competitive advantage and can opportu-
nistically expand or accumulate to ultimately give rise to large 
numbers of normal mature lymphocytes. Several factors have 
been implicated in the expansion of the early B cell and thy-
mocyte lineages, including IL-7 (24, 49), stem cell factor 
(50), Flt3 ligand (22, 51), and recently, various Wnt/Frizzled 
pathways (52). In the case of γc−/− animals, the pro–B-B 
population appears to have defects in IL-7–dependent expan-
sion, providing a proliferative advantage to wild-type donor 
cells at these stages (24, 53–56). RAG2−/− mice likely recon-
stitute more slowly because their lymphocytes can develop 
normally through the pro–B cell as well as DN3 thymocyte 
stages and occupy the appropriate stromal microenviron-
ments (31). However, because RAG2−/− lymphocytes can-
not advance past these stages (57), small numbers of developing 
donor-derived cells can expand and accumulate without 
competition at the pre–B as well as DN4 thymocyte cell 
stages and all subsequent developmental steps. Although it is 
possible that the donor LT-HSCs will only persist for fi  nite 
periods of time because of the considerable demand imposed 
by the  250,000-fold expansion to the lymphocyte stage, we 
have observed no meaningful decline in granulocyte or lym-
phocyte chimerism at any time point up to 30 wk after trans-
plantation of primary recipients. Nonetheless, because we 
have observed some declines in HSC potency after secondary 
transplantation (Fig. 3 B vs. Fig. 2 B), in clinical settings it 
would be advisable to keep donor LT-HSCs stored in the 
event that grafts do not persist indefi  nitely. Additionally, the 
low levels of granulocyte chimerism achieved from a single 
transplant are unlikely to be clinically useful for patients suf-
fering from myeloid defi  ciencies.
We also show conclusively that stable engraftment within 
these rare niches by minor histocompatibility–mismatched 
HSCs is tightly regulated by host CD4+ T cells. HSCs from 
CD45.1 mice cannot productively engraft unirradiated con-
genic CD45.2 mice, yet they routinely engraft the genetically 
unreactive F1 strain (CD45.1 × CD45.2). To our knowl-
edge, the only antigenic diff  erence between these strains is 
the CD45 allele, which is normally considered to be a rela-
tively innocuous congenic marker. Similarly, HSCs isolated 
from GFP-transgenic mice backcrossed to the C57BL/Ka 
genetic background cannot productively engraft wild-type 
C57BL/Ka mice. The only antigenic diff  erence  between 
these strains to our knowledge is the GFP gene product. 
These experiments prove that very small antigenic diff  erences 
lead to a complete rejection of donor HSC grafts in the ab-
sence of cytoreductive conditioning.
Encouragingly, however, the elimination of CD4+ T cell 
function allows for the functional and sustained engraftment of 
HSCs with minor histocompatibility mismatches in our system. 
Xu et al. (17) have shown that transient antibody-mediated 
depletion of host αβ T cells in mice enhances   engraftment 
of donor bone marrow with minor histocompatibility mis-
matches. Spitzer et al. (58) have shown that conditioning hap-
loidentical patients with a depleting α-CD2 antibody along 
with low-dose cytoreductive treatments before bone marrow 
transplantation allows, at the minimum, transient multilineage 
engraftment. Consistent with this, we demonstrate that tran-
sient antibody-mediated CD4+ T cell depletion alone is suf-
fi  cient to allow short-term engraftment of wild-type donor 
HSCs and restoration of B cells in a mouse model of non-
SCID. More complete CD4+ T cell depletions and/or better 
methods to increase donor-derived thymic dendritic cell con-
tribution might allow for lasting   donor hematopoiesis.
Even in the absence of inherited genetic mutations, both 
mice and humans develop diminished immune capacity with 
age. This progressive loss of immune function has recently 
Figure 10.  Transplanted HSC grafts are accepted more readily in 
aged recipients than in young mice. Purifi  ed eGFP+ HSCs were sorted 
and 1,750–4,000 cells were repetitively transplanted into 2-mo-old 
C57Bl6/Ka and 24-mo-old C57Bl6/Harland mice. Donor granulocyte, B 
cell, and T cell chimerism are shown from the fi  rst peripheral bleed taken 
at 6.5 wk after the fi  rst transplant (3 d after the fi  nal transplant). 
●, young recipients; ◇, aged recipients. The numbers of animals with no 
detectable chimerism in each group are listed below the dotted line.82  ENGRAFTMENT IN RARE EMPTY HEMATOPOIETIC STEM CELL NICHES | Bhattacharya et al.
been attributed to HSC-intrinsic defects in diff  erentiation to 
lymphoid-primed progenitors (29). Because we have dem-
onstrated that a very small number of properly functioning 
HSCs can mask the defects in a much larger pool of HSCs, it 
is tempting to speculate that age-related immune defects 
don’t become readily apparent until nearly all fully “young” 
HSCs are exhausted. The reintroduction of fully multipotent 
HSCs, perhaps obtained as an autologous sample earlier in 
life, might signifi  cantly delay age-related immune decline.
Numerous studies have shown how common condition-
ing treatments used before bone marrow transplantation, 
such as irradiation, cyclophosphamide, and busulfan, can 
cause serious side eff  ects, including lowered platelet counts, 
infertility, and secondary malignancies (59). When these cy-
totoxic therapies are used to treat hematologic malignancies, 
the side eff  ects must unfortunately be tolerated as a byproduct 
of necessary chemotherapy. The necessity of such condition-
ing treatments for hematopoietic defi  ciencies before HSC 
transplantation, however, should be reconsidered. Although 
it is true that available niche space is low under normal con-
ditions, we show that transplantation of modest numbers of 
highly purifi  ed HSCs can engraft the few niches that are 
available and correct lymphoid defi   ciencies. Thus, niche 
space is not an absolute limiting factor to HSC-mediated cor-
rection of B, T, or NK cell defi  ciencies.
Unlike the myeloablative regimens almost always per-
formed on non-SCID immunodefi  cient patients, SCID pa-
tients who receive MHC-matched CD34-enriched or T 
cell–depleted bone marrow grafts generally do not receive 
cytoreductive conditioning before transplantation (37, 60). 
However, it has been suggested that HSC engraftment does 
not occur in these patients (61). Because many of these pa-
tients show poor B cell lymphopoiesis and lose T cell counts 
with time, it has been proposed that the lymphoid correction 
occurs as a result of engraftment of short-lived progenitor 
cells, which along with mature cells constitute the vast ma-
jority of transplanted cells, rather than HSCs with full he-
matopoietic and self-renewal potential (62, 63). A careful 
examination of the data, however, shows that  0.8% of 
CD34+ cells in an unconditioned SCID patient who received 
a bone marrow transplant are not of host origin (61). Al-
though the authors, understandably, did not consider this 
level of engraftment meaningful, our results suggest that small 
numbers of HSCs have engrafted in these patients and that 
eventual T cell loss may be a refl  ection of HSC exhaustion 
rather than an initial failure to engraft. This hypothesis is re-
inforced by suggestions that the process of physiological HSC 
circulation seems to be conserved between mice and humans 
(16, 64, 65). Alternatively, the lack of B and T lymphopoiesis 
has correlated well with graft-versus-host disease (GVHD) in 
previous studies (66, 67). In MHC-matched settings, bone 
marrow grafts are often transplanted without manipulation, 
whereas in HLA-mismatched settings, T cell depletions or 
CD34 enrichments of donor marrow can still leave up to 104 
T cells/kg (37). Our results show that even in MHC-matched 
congenic mouse model systems, immune responses can rec-
ognize and reject very slightly mismatched cells, suggesting 
that it is very likely that GVH responses occur in all patients 
that receive any mature T cells as part of their nonautologous 
graft. Although GVHD may not be classifi  ed as clinically sig-
nifi  cant or obviously symptomatic in all cases, subtle GVH 
eff  ects on B and T lymphopoiesis might still occur. Thus, the 
use of purifi  ed HSC transplants, which do not cause GVHD 
(30), may potentially avoid poor B lymphopoiesis. In our 
mouse model system, we have observed sustained B and T 
lymphopoiesis for the duration of our experiments after puri-
fi  ed HSC transplantation.
The mechanism by which transplanted HSCs correct 
  hematopoietic defi  ciencies in our unconditioned recipients is 
applicable to the correction of many types of both SCID and 
non-SCID immunodefi  ciencies, but these studies at the same 
time clearly demonstrate that very subtle minor histocompat-
ibility diff  erences can mediate the rejection of HSC grafts 
when host T lymphocytes are present. Our data suggest that 
transplantation of purifi  ed HSCs, in combination with highly 
specifi   c lymphoablative treatments when necessary, can 
correct lymphoid defi  ciencies in immunodefi  cient patients 
without the undesired side eff  ects, such as toxic conditioning 
and GVHD, often associated with current conditioning and 
transplantation regimens. Future experiments will determine 
if the same strategy can be applied to the correction of my-
eloid defi  ciencies.
MATERIALS AND METHODS
Animals. All animal procedures were approved by the International Animal 
Care and Use Committee. C57BL/Ka-Thy1.1 CD45.2+ (HZ) and C57BL/
Ka-Thy1.1 CD45.1 (BA) strains were derived and maintained in our labora-
tory. eGFP transgenic mice used in these studies were backcrossed at least 20 
generations to either the BA or HZ strain. C57Bl6/Harland mice used for 
the aging studies were obtained from the National Institute of Aging. The 
RAG2−/−, RAG2−/−γc−/−, I-A−/−, and β2m−/− mice have been described 
previously (19, 32, 36, 57) and were bred at least 20 generations onto the 
C57BL/Ka-Thy1.2 CD45.1+, C57BL/Ka-Thy1.2 CD45.2+, and C57BL/
Ka-Thy1.1 CD45.2 backgrounds. TCRα−/−β−/− mice were provided by 
J. Campbell and M. Davis (Stanford University, Stanford, CA). Cμ−/− mice 
were provided by J. Tung and L. Herzenberg (Stanford University). Periph-
eral blood was sampled from the tail vein, and all HSC transplants were per-
formed by injection into the retroorbital sinus of isofl  urane-anesthetized 
mice. For repetitive transplants, between 1,750 and 4,000 HSCs were trans-
planted weekly for 6 wk. Donor mice were 4–6-wk old, and recipient mice 
ranged from 4–12 wk of age unless otherwise noted.
Antibodies. The following monoclonal antibodies were purifi  ed and con-
jugated using hybridomas maintained in our laboratory: 19XE5 (anti-
Thy1.1), 2C11 (anti-CD3), GK1.5 (anti-CD4), 53-7.3 (anti-CD5), 53-6.7 
(anti-CD8), 6B2 (anti-B220), 8C5 (anti–Gr-1), M1/70 (anti–Mac-1), 
TER119 (anti-Ter119), A20.1.7 (anti-CD45.1), AL1-4A2 (anti-CD45.2), 
2B8 (anti–c-kit), E13-161-7 (anti–Sca-1), anti-CD16/CD32 (2.4G2), and 
A7R34 (anti–IL-7 receptor α). Antibodies were conjugated to biotin, PE, 
allophycocyanin (APC), Alexa 405, Alexa 430, or Alexa 488 (Invitrogen), 
according to the manufacturer’s instructions. The following were purchased 
from eBiosciences: antibodies against CD3, CD4, CD8, B220, Mac-1, 
Ter119, and Gr-1 conjugated to PE-Cy5; anti–c-kit and anti–Mac-1 conju-
gated to PE-Cy7; anti–Sca-1 conjugated to PE-Cy5.5; anti-CD45.1 and 
anti-CD45.2 (104) conjugated to APC-Cy5.5; anti-B220 conjugated to 
APC-Cy7; anti-Flk2 (A2F10) conjugated to PE or biotin; and streptavidin 
conjugated to APC. Anti-CD34 (RAM34) conjugated to FITC or biotin, JEM VOL. 203, January 23, 2006  83
ARTICLE
anti-TCRβ (H57-597) conjugated to APC, anti-CD43 (1B11) conjugated 
to PE, anti–I-A/I-E (M5.114.15.2) conjugated to PE, and anti-Ly51 (6C3) 
conjugated to biotin were purchased from BD Biosciences. Streptavidin 
conjugated to APC-Cy7 was purchased from Caltag.
FACS and analysis. All cells were sorted on a FACSVantage or a FACS Aria 
(Becton Dickinson). All peripheral blood analysis was performed on an LSR-
Scan (Becton Dickinson). Peripheral blood was obtained from the tail vein, red 
blood cells were sedimented with 2% dextran, and the remaining red blood 
cells were lysed with an ammonium chloride solution. The remaining white 
blood cells were stained with anti-CD45.2–Alexa 488, anti–CD45.1-PE, anti–
Ter119-PE-Cy5, anti–Mac-1–PE-Cy7, anti–TCRβ-APC, and anti–B220-
APC–Cy7. When peripheral blood containing eGFP+ cells was analyzed, 
anti-CD45.1–Alexa-488 was omitted and anti–Gr-1–PE was used instead of 
anti–CD45.2-PE if warranted by the experiment. For HSC isolation, bone 
marrow was fi  rst enriched using anti–c-kit beads and immunomagnetic selec-
tion was performed on an AutoMACS machine (Miltenyi Biotec). Enriched 
cells were stained with anti–CD34-FITC, anti–Flk2-PE, anti-lineage (CD3, 
CD4, CD8, B220, Ter119, Mac-1, Gr-1)–PE-Cy5, anti–Sca-1–PE-Cy5.5, 
and anti–c-kit–PE-Cy7, and cells were double sorted before transplantation. 
For analysis of HSC chimerism, CD45.1–APC-Cy5.5 was included, and 
CD34 staining was achieved with anti-CD34 biotin followed by streptavidin 
APC. For isolation of HSCs from eGFP-transgenic mice, cells were stained 
with anti-lineage–Cy5-PE, anti–Sca-1–PE-Cy5.5, anti–c-kit–PE-Cy7, anti–
Flk2-PE, and anti-CD34 biotin followed by streptavidin APC. For analysis of 
eGFP HSC chimerism, anti–CD45.1-APC–Cy5.5 was included.
Immunizations. Mice were immunized intraperitoneally with 100 μg NP 
conjugated to chicken γ globulin (Biosearch Technologies) precipitated in 
10% aluminum potassium sulfate (Sigma-Aldrich). NP-specifi  c  enzyme-
linked immunosorbent assays were performed with serum obtained 1 wk af-
ter immunization on high-protein binding 96-well plates coated with 5 μg 
NP-BSA (Biosearch Technologies). Wells were developed with anti–mouse 
IgG-horseradish peroxidase (Southern Biotechnology Associates, Inc.) fol-
lowed by 1 mg/ml ABTS reagent (Sigma-Aldrich), and the reactions were 
stopped by the addition of 0.1% sodium azide (Sigma-Aldrich). Absorbance 
was read at a wavelength of 405 nm.
In vivo depletion of CD4+ T cells. Mice were treated consecutively for 
3 d with 500 μg of intravenously injected purifi   ed anti-CD4 antibody 
(GK1.5). Peripheral blood was analyzed for TCRβ and CD8 expression to 
quantitatively assess CD4+ T cell depletion relative to untreated animals. 
These mice were then transplanted with 800 GFP+ HSCs 1 d after the third 
injection. The mice were then given weekly injections of anti-CD4 for the 
fi  rst 3 wk after HSC transplantation and left untreated afterward.
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